A major nomenclature shift from NAFLD to Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) has reshaped how clinicians view fatty liver disease. The change emphasizes its metabolic roots—obesity, T2DM, dyslipidemia, and hypertension making it highly relevant across general practice, endocrinology, cardiology, and hepatology. With rising global metabolic syndrome prevalence, MASLD is now one of the most searched liver conditions among doctors. The challenge is its silent course.
Many patients remain asymptomatic despite ongoing hepatic inflammation and fibrosis. Mild ALT elevations or incidental fatty liver on ultrasound should prompt structured evaluation. Non-invasive tools such as FIB-4, NAFLD fibrosis score, and transient elastography are increasingly recommended for early risk stratification in outpatient settings to identify those at risk for advanced fibrosis. …
